Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_assertion type Assertion NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_head.
- NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_assertion description "[We apply this paradigm to study mesothelin (MSLN) overexpression, a nearly ubiquitous, diagnostically and therapeutically useful characteristic of pancreatic cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_provenance.
- NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_assertion evidence source_evidence_literature NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_provenance.
- NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_assertion SIO_000772 17909009 NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_provenance.
- NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_assertion wasDerivedFrom befree-20140225 NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_provenance.
- NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_assertion wasGeneratedBy ECO_0000203 NP410626.RA3FbQQvk6j9XNCuvbYgQYttFekgnmjtpZIz0H0zXNxWI130_provenance.